Last reviewed · How we verify
Vortioxetine (Lu AA21004)
Vortioxetine is a serotonin modulator and stimulator that acts as a selective 5-HT3 receptor antagonist, 5-HT1A receptor agonist, 5-HT7 receptor agonist, and norepinephrine reuptake inhibitor.
Vortioxetine is a serotonin modulator and stimulator that acts as a selective 5-HT3 receptor antagonist, 5-HT1A receptor agonist, 5-HT7 receptor agonist, and norepinephrine reuptake inhibitor. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | Vortioxetine (Lu AA21004) |
|---|---|
| Also known as | Brintellix, Brintellix® |
| Sponsor | H. Lundbeck A/S |
| Drug class | Serotonin modulator and stimulator |
| Target | 5-HT3 receptor, 5-HT1A receptor, 5-HT7 receptor, norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
This unique mechanism of action allows vortioxetine to modulate multiple serotonin receptors and reuptake transporters, which contributes to its antidepressant effects. By modulating these receptors, vortioxetine can increase the levels of serotonin in the brain, which can help to improve mood and reduce symptoms of depression. Additionally, vortioxetine's effects on the 5-HT3 receptor may contribute to its anxiolytic and anti-emetic properties.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Dry mouth
Key clinical trials
- Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study (PHASE2)
- Adjunctive Vortioxetine in Schizophrenia (PHASE4)
- Vortioxetine Adjunctive Treatment in Bipolar Depression (PHASE4)
- Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome (PHASE3)
- Tolerability, Safety and Efficacy of Vortioxetine (PHASE4)
- Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment (PHASE4)
- Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets (PHASE1)
- Vortioxetine to Prevent Return of Symptoms in Children With Depression (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vortioxetine (Lu AA21004) CI brief — competitive landscape report
- Vortioxetine (Lu AA21004) updates RSS · CI watch RSS
- H. Lundbeck A/S portfolio CI